Engineering therapeutic protein disaggregases

Molecular Biology of the Cell

Volumn 27, Issue 10, 2016, Pages 1556-1560

  Shorter, James ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE; HEAT SHOCK PROTEIN 110; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; PEPTIDES AND PROTEINS; PROTEIN DISAGGREGASE; UNCLASSIFIED DRUG; ALPHA SYNUCLEIN; DNA BINDING PROTEIN; HEAT SHOCK PROTEIN; PROTEIN AGGREGATE; SACCHAROMYCES CEREVISIAE PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELL NUCLEUS; CYTOPLASM; DEGENERATIVE DISEASE; DISEASE COURSE; ENDOPLASMIC RETICULUM; GENE MUTATION; HUMAN; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN ENGINEERING; PROTEIN FOLDING; REVIEW; ANIMAL; DRUG EFFECTS; METABOLISM; NEURODEGENERATIVE DISEASES; PHYSIOLOGY; PROCEDURES; SACCHAROMYCES CEREVISIAE;

ALPHA-SYNUCLEIN; ANIMALS; DNA-BINDING PROTEINS; HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PROTEIN AGGREGATES; PROTEIN ENGINEERING; PROTEIN FOLDING; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS;

EID: 84968608566     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E15-10-0693     Document Type: Review

References (75)

1. Abisambra J, Jinwal UK, Miyata Y, Rogers J, Blair L, Li X, Seguin SP, Wang L, Jin Y, Bacon J, et al. (2013). Allosteric heat shock protein 70 inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau. Biol Psychiatry 74, 367-374.
2. Aponte RA, Zimmermann S, Reinstein J (2010). Directed evolution of the DnaK chaperone: mutations in the lid domain result in enhanced chaperone activity. J Mol Biol 399, 154-167.
3. Baltimore D, Berg P, Botchan M, Carroll D, Charo RA, Church G, Corn JE, Daley GQ, Doudna JA, Fenner M, et al. (2015). Biotechnology. A prudent path forward for genomic engineering and germline gene modification. Science 348, 36-38.
4. Bobkova NV, Evgen'ev M, Garbuz DG, Kulikov AM, Morozov A, Samokhin A, Velmeshev D, Medvinskaya N, Nesterova I, Pollock A, et al. (2015). Exogenous Hsp70 delays senescence and improves cognitive function in aging mice. Proc Natl Acad Sci USA 112, 16006-16011.
5. Bobkova NV, Garbuz DG, Nesterova I, Medvinskaya N, Samokhin A, Alexandrova I, Yashin V, Karpov V, Kukharsky MS, Ninkina NN, et al. (2014). Therapeutic effect of exogenous hsp70 in mouse models of Alzheimer's disease. J Alzheimers Dis 38, 425-435.
6. Callaway E (2016). UK scientists gain licence to edit genes in human embryos. Nature 530, 18.
7. Campioni M, Severino A, Manente L, Tuduce IL, Toldo S, Caraglia M, Crispi S, Ehrmann M, He X, Maguire J, et al. (2010). The serine protease HtrA1 specifically interacts and degrades the tuberous sclerosis complex 2 protein. Mol Cancer Res 8, 1248-1260.
8. Chien J, He X, Shridhar V (2009). Identification of tubulins as substrates of serine protease HtrA1 by mixture-based oriented peptide library screening. J Cell Biochem 107, 253-263.
9. Cohen SI, Linse S, Luheshi LM, Hellstrand E, White DA, Rajah L, Otzen DE, Vendruscolo M, Dobson CM, Knowles TP (2013). Proliferation of amyloid-beta42 aggregates occurs through a secondary nucleation mechanism. Proc Natl Acad Sci USA 110, 9758-9763.
10. Cushman M, Johnson BS, King OD, Gitler AD, Shorter J (2010). Prion-like disorders: blurring the divide between transmissibility and infectivity. J Cell Sci 123, 1191-1201.
11. Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, Singleton A, Olanow CW, Merchant KM, Bezard E, et al. (2015). Targeting alpha-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol 14, 855-866.
12. DeSantis ME, Leung EH, Sweeny EA, Jackrel ME, Cushman-Nick M, Neuhaus-Follini A, Vashist S, Sochor MA, Knight MN, Shorter J (2012). Operational plasticity enables hsp104 to disaggregate diverse amyloid and nonamyloid clients. Cell 151, 778-793.
13. DeSantis ME, Shorter J (2012). The elusive middle domain of Hsp104 and ClpB: location and function. Biochim Biophys Acta 1823, 29-39.
14. Deverman BE, Pravdo PL, Simpson BP, Kumar SR, Chan KY, Banerjee A, Wu WL, Yang B, Huber N, Pasca SP, et al. (2016). Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol 34, 204-209.
15. Dixit R, Ross JL, Goldman YE, Holzbaur EL (2008). Differential regulation of dynein and kinesin motor proteins by tau. Science 319, 1086-1089.
16. Dong Z, Wolfer DP, Lipp HP, Bueler H (2005). Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease. Mol Ther 11, 80-88.
17. Doudna JA, Charpentier E (2014). Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258096.
18. Duennwald ML, Echeverria A, Shorter J (2012). Small heat shock proteins potentiate amyloid dissolution by protein disaggregases from yeast and humans. PLoS Biol 10, e1001346.
19. Eisele YS, Monteiro C, Fearns C, Encalada SE, Wiseman RL, Powers ET, Kelly JW (2015). Targeting protein aggregation for the treatment of degenerative diseases. Nat Rev Drug Discov 14, 759-780.
20. Erives AJ, Fassler JS (2015). Metabolic and chaperone gene loss marks the origin of animals: evidence for Hsp104 and Hsp78 chaperones sharing mitochondrial enzymes as clients. PLoS One 10, e0117192.
21. Farrell CM, Baker TA, Sauer RT (2007). Altered specificity of a AAA+ protease. Mol Cell 25, 161-166.
22. Fedele E, Rivera D, Marengo B, Pronzato MA, Ricciarelli R (2015). Amyloid beta: walking on the dark side of the moon. Mech Ageing Dev 152, 1-4.
23. Finka A, Sharma SK, Goloubinoff P (2015). Multi-layered molecular mechanisms of polypeptide holding, unfolding and disaggregation by HSP70/ HSP110 chaperones. Front Mol Biosci 2, 29.
24. Fontaine SN, Martin MD, Akoury E, Assimon VA, Borysov S, Nordhues BA, Sabbagh JJ, Cockman M, Gestwicki JE, Zweckstetter M, et al. (2015). The active Hsc70/tau complex can be exploited to enhance tau turnover without damaging microtubule dynamics. Hum Mol Genet 24, 3971-3981.
25. Gao X, Carroni M, Nussbaum-Krammer C, Mogk A, Nillegoda NB, Szlachcic A, Guilbride DL, Saibil HR, Mayer MP, Bukau B (2015). Human Hsp70 disaggregase reverses Parkinson's-linked alpha-synuclein amyloid fibrils. Mol Cell 59, 781-793.
26. Gifondorwa DJ, Jimenz-Moreno R, Hayes CD, Rouhani H, Robinson MB, Strupe JL, Caress J, Milligan C (2012). Administration of recombinant heat shock protein 70 delays peripheral muscle denervation in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Neurol Res Int 2012, 170426.
27. Gifondorwa DJ, Robinson MB, Hayes CD, Taylor AR, Prevette DM, Oppenheim RW, Caress J, Milligan CE (2007). Exogenous delivery of heat shock protein 70 increases lifespan in a mouse model of amyotrophic lateral sclerosis. J Neurosci 27, 13173-13180.
28. Gitler AD (2008). Beer and bread to brains and beyond: can yeast cells teach us about neurodegenerative disease? Neurosignals 16, 52-62.
29. Gitler AD, Shorter J (2011). RNA-binding proteins with prion-like domains in ALS and FTLD-U. Prion 5, 179-187.
30. Guo L, Giasson BI, Glavis-Bloom A, Brewer MD, Shorter J, Gitler AD, Yang X (2014). A cellular system that degrades misfolded proteins and protects against neurodegeneration. Mol Cell 55, 15-30.
31. Guo JL, Lee VM (2014). Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med 20, 130-138.
32. Jackrel ME, DeSantis ME, Martinez BA, Castellano LM, Stewart RM, Caldwell KA, Caldwell GA, Shorter J (2014a). Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. Cell 156, 170-182.
33. Jackrel ME, Shorter J (2014). Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins. Dis Model Mech 7, 1175-1184.
34. Jackrel ME, Shorter J (2015). Engineering enhanced protein disaggregases for neurodegenerative disease. Prion 9, 90-109.
35. Jackrel ME, Tariq A, Yee K, Weitzman R, Shorter J (2014b). Isolating potentiated Hsp104 variants using yeast proteinopathy models. J Vis Exp 93, e52089.
36. Jackrel ME, Yee K, Tariq A, Chen AI, Shorter J (2015). Disparate mutations confer therapeutic gain of Hsp104 function. ACS Chem Biol 10, 2672-2679.
37. Jo H, Patterson V, Stoessel S, Kuan CY, Hoh J (2014). Protoporphyrins enhance oligomerization and enzymatic activity of HtrA1 serine protease. PLoS One 9, e115362.
38. Johnson BS, McCaffery JM, Lindquist S, Gitler AD (2008). A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci USA 105, 6439-6444.
39. Jucker M, Walker LC (2011). Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 70, 532-540.
40. Khurana V, Tardiff DF, Chung CY, Lindquist S (2015). Toward stem cell-based phenotypic screens for neurodegenerative diseases. Nat Rev Neurol 11, 339-350.
41. Kilpatrick K, Novoa JA, Hancock T, Guerriero CJ, Wipf P, Brodsky JL, Segatori L (2013). Chemical induction of Hsp70 reduces alpha-synuclein aggregation in neuroglioma cells. ACS Chem Biol 8, 1460-1468.
42. King OD, Gitler AD, Shorter J (2012). The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res 1462, 61-80.
43. Kormann MS, Hasenpusch G, Aneja MK, Nica G, Flemmer AW, Herber- Jonat S, Huppmann M, Mays LE, Illenyi M, Schams A, et al. (2011). Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 29, 154-157.
44. Lo Bianco C, Shorter J, Regulier E, Lashuel H, Iwatsubo T, Lindquist S, Aebischer P (2008). Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest 118, 3087-3097.
45. Mack KL, Shorter J (2016). Engineering and evolution of molecular chaperones and protein disaggregases with enhanced activity. Front Mol Biosci 3, 8.
46. March ZM, King OD, Shorter J (2016). Prion-like domains as epigenetic regulators, scaffolds for subcellular organization, and drivers of neurodegenerative disease. Brain Res 2016, S0006-8993(16)30096-8.
47. Mattoo RU, Sharma SK, Priya S, Finka A, Goloubinoff P (2013). Hsp110 is a bona fide chaperone using ATP to unfold stable misfolded polypeptides and reciprocally collaborate with Hsp70 to solubilize protein aggregates. J Biol Chem 288, 21399-21411.
48. Miyata Y, Li X, Lee HF, Jinwal UK, Srinivasan SR, Seguin SP, Young ZT, Brodsky JL, Dickey CA, Sun D, et al. (2013). Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels. ACS Chem Neurosci 4, 930-939.
49. Morishima Y, Lau M, Peng HM, Miyata Y, Gestwicki JE, Pratt WB, Osawa Y (2011). Heme-dependent activation of neuronal nitric oxide synthase by cytosol is due to an Hsp70-dependent, thioredoxin-mediated thioldisulfide interchange in the heme/substrate binding cleft. Biochemistry 50, 7146-7156.
50. Nagel F, Falkenburger BH, Tonges L, Kowsky S, Poppelmeyer C, Schulz JB, Bahr M, Dietz GP (2008). Tat-Hsp70 protects dopaminergic neurons in midbrain cultures and in the substantia nigra in models of Parkinson's disease. J Neurochem 105, 853-864.
51. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130-133.
52. Nillegoda NB, Kirstein J, Szlachcic A, Berynskyy M, Stank A, Stengel F, Arnsburg K, Gao X, Scior A, Aebersold R, et al. (2015). Crucial HSP70 co-chaperone complex unlocks metazoan protein disaggregation. Nature 524, 247-251.
53. Outeiro TF, Lindquist S (2003). Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302, 1772-1775.
54. Poepsel S, Sprengel A, Sacca B, Kaschani F, Kaiser M, Gatsogiannis C, Raunser S, Clausen T, Ehrmann M (2015). Determinants of amyloid fibril degradation by the PDZ protease HTRA1. Nat Chem Biol 11, 862-869.
55. Pratt WB, Gestwicki JE, Osawa Y, Lieberman AP (2015). Targeting Hsp90/ Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases. Annu Rev Pharmacol Toxicol 55, 353-371.
56. Rahdar M, McMahon MA, Prakash TP, Swayze EE, Bennett CF, Cleveland DW (2015). Synthetic CRISPR RNA-Cas9-guided genome editing in human cells. Proc Natl Acad Sci USA 112, E7110-7117.
57. Rampelt H, Kirstein-Miles J, Nillegoda NB, Chi K, Scholz SR, Morimoto RI, Bukau B (2012). Metazoan Hsp70 machines use Hsp110 to power protein disaggregation. EMBO J 31, 4221-4235.
58. Robberecht W, Philips T (2013). The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci 14, 248-264.
59. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, et al. (2005). Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481.
60. Schweizer RS, Aponte RA, Zimmermann S, Weber A, Reinstein J (2011). Fine tuning of a biological machine: DnaK gains improved chaperone activity by altered allosteric communication and substrate binding. Chembiochem 12, 1559-1573.
61. Shorter J (2011). The mammalian disaggregase machinery: Hsp110 synergizes with Hsp70 and Hsp40 to catalyze protein disaggregation and reactivation in a cell-free system. PLoS One 6, e26319.
62. Shrestha L, Patel HJ, Chiosis G (2016). Chemical tools to investigate mechanisms associated with HSP90 and HSP70 in disease. Cell Chem Biol 23, 158-172.
63. Smith BA, Mularz AE, Hecht MH (2015). Divergent evolution of a bifunctional de novo protein. Protein Sci 24, 246-252.
64. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, et al. (2010). The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 5, e9505.
65. Sun Z, Diaz Z, Fang X, Hart MP, Chesi A, Shorter J, Gitler AD (2011). Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol 9, e1000614.
66. Sweeny EA, Shorter J (2015). Mechanistic and structural insights into the prion-disaggregase activity of Hsp104. J Mol Biol 2015, S0022- 2836(15)00678-6.
67. Tennstaedt A, Popsel S, Truebestein L, Hauske P, Brockmann A, Schmidt N, Irle I, Sacca B, Niemeyer CM, Brandt R, et al. (2012). Human high temperature requirement serine protease A1 (HTRA1) degrades tau protein aggregates. J Biol Chem 287, 20931-20941.
68. Tiaden AN, Richards PJ (2013). The emerging roles of HTRA1 in musculoskeletal disease. Am J Pathol 182, 1482-1488.
69. Torrente MP, Castellano LM, Shorter J (2014). Suramin inhibits Hsp104 ATPase and disaggregase activity. PLoS One 9, e110115.
70. Torrente MP, Chuang E, Noll MM, Jackrel ME, Go MS, Shorter J (2016). Mechanistic insights into Hsp104 potentiation. J Biol Chem 291, 5101-5115.
71. Torrente MP, Shorter J (2013). The metazoan protein disaggregase and amyloid depolymerase system: Hsp110, Hsp70, Hsp40, and small heat shock proteins. Prion 7, 457-463.
72. Trojanowski JQ, Lee VM (2005). Pathological tau: a loss of normal function or a gain in toxicity? Nat Neurosci 8, 1136-1137.
73. Wang AM, Miyata Y, Klinedinst S, Peng HM, Chua JP, Komiyama T, Li X, Morishima Y, Merry DE, Pratt WB, et al. (2013). Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation. Nat Chem Biol 9, 112-118.
74. Wang JD, Herman C, Tipton KA, Gross CA, Weissman JS (2002). Directed evolution of substrate-optimized GroEL/S chaperonins. Cell 111, 1027-1039.
75. Wisen S, Bertelsen EB, Thompson AD, Patury S, Ung P, Chang L, Evans CG, Walter GM, Wipf P, Carlson HA, et al. (2010). Binding of a small molecule at a protein-protein interface regulates the chaperone activity of hsp70-hsp40. ACS Chem Biol 5, 611-622.